Advertisement

Pharmacy World and Science

, Volume 19, Issue 2, pp 60–69 | Cite as

Antiepileptic drug treatment in the nineties in The Netherlands.

  • D.G.A. Kasteleijn‐Nolst TrenitÄ
  • P.M. Edelbroek
Article

Abstract

In this review the ‘state of the art’ of treating patients with epilepsy in the nineties in the Netherlands is presented. It describes general strategies for treatment with antiepileptic drugs and the history of development of the classical anticonvulsant drugs. Eight new drugs, including vigabatrin, lamotrigine, felbamate, oxcarbazepine, gabapentin, tiagabine, levetiracetam and topiramate are discussed. A review of their pharmacological and clinical properties is presented. Dutch experience with these drugs is included.

Epilepsy treatment Antiepileptic drugs Pharmacology Pharmacokinetics Vigabatrin Lamotrigine Felbamate Oxcarbazepine Gabapentin Tiagabine Levetiracetam Topiramate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Engel J, Jr. Seizures and Epilepsy. Philadelphia: F.A. Davis Co, 1989.Google Scholar
  2. 2.
    Hauser X. Epidemiology of Epilepsy. In: Handbook of Neuroepidemiology. USA: Marcel Dekker Inc., 1994.Google Scholar
  3. 3.
    Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389‐399.Google Scholar
  4. 4.
    Sonnen AEH, De Puit M, Peek MEM. Alternatieve geneeswij‐zen en epilepsie. Publication of Dutch Epilepsy Society 1991;59‐101.Google Scholar
  5. 5.
    Britton JW, So EL. New Antiepileptic Drugs: Prospects for the Future. J. Epilepsy 1995;8:267‐281.Google Scholar
  6. 6.
    Graves NM, Leppik IE. Advances in pharmacotherapy: recent developments in the treatment of epilepsy. J. Clin. Pharm Ther. 1993;18:227‐242.Google Scholar
  7. 7.
    Davies JA. Mechanisms of action of antiepileptic drugs. Seizure 1995;4:267‐272.Google Scholar
  8. 8.
    Brodie MJ, Dichter MA. Antiepileptic Drugs. N.Eng.J.Med. 1996;334(3):168‐175.Google Scholar
  9. 9.
    Patsalos PN. Phenobarbitone to gabapentin: a guide to 82 years of anti‐epileptic drug pharmacokinetic interactions. Seizure 1994;3:163‐170.Google Scholar
  10. 10.
    Löscher W., Schmidt D. New drugs for the treatment of epilepsy. Curr.Opin.Invest. Drugs 1993;2(10):1067‐1095.Google Scholar
  11. 11.
    Sussman NM, Heydorn WE. New and investigational antiepi leptic drugs. Exp.Opin.Invest. Drugs 1994;3(4):355‐368.Google Scholar
  12. 12.
    Harden CL. New antiepileptic drugs. Neurology 1994;44:787‐795.Google Scholar
  13. 13.
    Rogawski MA, Porter RJ. Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with con sideration of promising developmental stage compounds. Pharmacol Rev 1990;42(3):223‐286.Google Scholar
  14. 14.
    Rowan AJ, Binnie CD, Warfield CA, Meinardi H, Meijer JWA. The delayed effect of sodium valproate on the photoconvul sive response in man. Epilepsia 1979;20:61‐68.Google Scholar
  15. 15.
    Meijer JWA. Knowledge, attitude and practice in antiepileptic drug monitoring. Thesis, Nijmegen,1991.Google Scholar
  16. 16.
    Scott DF. The history of epileptic therapy. England: The Parthenon Publishing Group, 1993.Google Scholar
  17. 17.
    Joosten JHH. Epilepsie. Amsterdam: Scheltema & Holkema's Boekhandel en Uitgeversmaatschappij N.V, 1941.Google Scholar
  18. 18.
    Krall RL, Penry JK, Kupferberg HJ, Swinyard EA. Antiepileptic Drug Development: I History and a program for progress. Epilepsia 1978;19:393‐408.Google Scholar
  19. 19.
    Richards RK, Everett GM. Analgesic and anticonvulsive properties of 3,5,5,‐trimethyloxazolidine‐2,4‐dione (Tridione). In Fed Proc 3:39,1944.Google Scholar
  20. 20.
    Lennox WG. Tridione in treatment of epilepsy. JAMA 1947;138‐143.Google Scholar
  21. 21.
    Trimble MR. Anticonvulsant drugs: mood and cognitive function. In: Epilepsy, Behaviour and cognitive function. Chichester: John Wiley, 1987;135‐43Google Scholar
  22. 22.
    MacDonald RL, Meldrum BS. General principles: Principles of antiepileptic drug action. In: Antiepileptic Drugs. 4th ed. New York: Raven Press, 1995:61‐77.Google Scholar
  23. 23.
    Chapman AG, Meldrum BS, Mendes E. Acute anticonvulsant activity of structural analogues of valproic acid and changes in brain GABA and aspartate content. Life Science 1983;32:2023‐2031.Google Scholar
  24. 24.
    Fariello RG, Varasi M, Smith MC. Valproic acid: Mechanisms of action. In: Antiepileptic Drugs. 4th ed. New York: Raven Press, 1995:581‐588.Google Scholar
  25. 25.
    Löscher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res 1994;17:95‐134.Google Scholar
  26. 26.
    Sander JWAS, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J Neurol Neurosurg & Psychiatry 1991:54;435‐439.Google Scholar
  27. 27.
    Mumford JP, Lewis PJ. Vigabatrin. In: New antiepileptic Drugs Elsevier, Amsterdam, 1991;22:161‐168.Google Scholar
  28. 28.
    Richens A. Potential antiepileptic drugs, Vigabatrin. In: Antiepileptic Drugs. Third Edition. Raven Press, Ltd., New York. 1989;937‐946.Google Scholar
  29. 29.
    Rey E, Pons G, Olive G. Vigabatrin. Clinical pharmacokinet ics. Clin. Pharmacokinet 1992;23(4):267‐278.Google Scholar
  30. 30.
    Gram L. Experimental studies and controlled clinical testing of valproate and vigabatrin. Acta Neurol Scand 1988:78;241‐270.Google Scholar
  31. 31.
    Petroff OAC, Rothman DL, Behar KL, Mattson RH. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology 1996;46:1459‐1463.Google Scholar
  32. 32.
    Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ et al. A multi‐centre study of vigabatrin for drug‐resistant epilepsy. Brit J Clin Pharm 1989;27(supp.1):95S‐100S.Google Scholar
  33. 33.
    Foletti GB, Delisle MC, Bachmann C. Reduction of Plasma Alanine Aminotransferase During Vigabatrin Treatment. Epilepsia 1995;36(8):804‐809.Google Scholar
  34. 34.
    Ryan MF, Samy A, Young J. Vigabatrin causes profound reduction in serum alanine transaminase activity. Ann Clin Biochem 1996;33:257‐258.Google Scholar
  35. 35.
    Van Parys JAP, De Beer‐Pawlikowski NKB, Edelbroek PM. Vigabatrin and serum aminotranferases. Epilepsia 1995;36(3):S108.[abstract]Google Scholar
  36. 36.
    Löscher W, Fassbender CP, Gram L, Gramer M, Hörstermann D, Zahner B. Stefan H. Determination of GABA and vigaba trin in human plasma by a rapid and simple HPLC method: correlation between clinical response to vigabatrin and increase in plasma GABA. Epilepsy Res. 1993;14:245‐255.Google Scholar
  37. 37.
    Fitton A, Goa KL. Lamotrigine. An Update of its Pharmacology and Therapeutic use in Epilepsy. Drugs 1995;50(4):691‐713.Google Scholar
  38. 38.
    Goa KL, Ross SR, Chrisp P. Lamotrigine. A Review of its Pharmacological Properties and Clinical Efficacy in Epilepsy. Drugs 1993;46(1):152‐176.Google Scholar
  39. 39.
    Rambeck B, Wolf P. Lamotrigine Clinical Pharmacokinetics. Clin. Pharmacokinet. 1993;25(6):433‐443.Google Scholar
  40. 40.
    Kilpatrick ES, Forrest G, Brodie MJ. Concentration‐Effect and Concentration‐Toxicity Relations with Lamotrigine: A Prospective Study. Epilepsia 1996;37(6):534‐538.Google Scholar
  41. 41.
    Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticon vulsant activity and neurotoxicity of felbamate and four pro totype antiepileptic drugs in mice and rats. Epilepsia: 27;27‐34.Google Scholar
  42. 42.
    Pellock JM, Boggs G. Felbamate: A Unique Anticonvulsant. Drugs of today 1995;31:1:9‐17.Google Scholar
  43. 43.
    Kucharczyk N. Felbamate: Chemistry and Biotransformation. In: Antiepileptic Drugs, 4th ed. Raven Press, Ltd. New York,1995,799‐806.Google Scholar
  44. 44.
    Perhach JL, Shumaker RC. Felbamate: Absorption, Distibution, and Excretion. In: Antiepileptic Drugs, 4th ed. Raven Press, Ltd. New York, 1995,807‐812.Google Scholar
  45. 45.
    Harden CL, Trifiletti R, Kutt H. Felbamate Levels in Patients with Epilepsy. Epilepsia 1996;37(3):280‐283.Google Scholar
  46. 46.
    Bebin EM, Sofia RD, Dreifuss FE. Felbamate, Toxiciy. In: Antiepileptic drugs 4th ed. New York: Raven Press, 1995:823‐7.Google Scholar
  47. 47.
    O'Neil MG, Perdun CS, Wilson MB, McGown ST, Platel S. Febamate‐associated fatal acute hepatic necrosis. Neurology 1996;46:1457‐9.Google Scholar
  48. 48.
    Grant SM, Faulds D. Oxcarbazepine. A review of its Pharmacology and Therapeutic Potential in Epilepsy, Trigemial Neuralgia and Affective Disorders. Drugs 1992;43(6):873‐888.Google Scholar
  49. 49.
    Schmutz M, Brugger F, Gentsch C, Mc Lean MJ, Olpe HR. Oxcarbazepine: Preclinical Anticonvulsant Profile and Putative Mechanisms of Action. Epilepsia 1994;35(5):S47‐S50.Google Scholar
  50. 50.
    Keränen T, Möbius HJ, Schurr‐Eisinger S. et al. Effect of Oxcarbazepine on Hepatic Clearance of Antipyrine in Patients with Previously Untreated Epilepsy. Epilepsia 1995;36(3):S161.[abstract]Google Scholar
  51. 51.
    Van Parys, JAP, Meijer JWA, Edelbroek PM. Comparison of enzyme induction by various antiepileptic drugs including oxcarbazepine and vigabatrin. Epilepsia 1995;36(3):S161.[‐abstract]Google Scholar
  52. 52.
    Saano V, Schurr‐Eisinger S, Möbius HJ. et al. Effect of Oxcarbazepine on Antipyrine Metabolism in Healthy Volunteers. Epilepsia 1995;36(3):S161.[abstract]Google Scholar
  53. 53.
    Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L et al. Therapeutic experiences with 947 epileptic out‐patients in oxcarbazepine treatment. Acta Neurol Scand. 1993;87:224‐227.Google Scholar
  54. 54.
    Taylor CP. Emerging prospectives on the mechanism of action of gabapentin. Neurology 1994;44(Suppl 5):S10‐S16.Google Scholar
  55. 55.
    Goldlust A, Su TZ, Weltry DF, Taylor ChP, Oxender DL. Effects of anticonvulsant drug gabapentin on the enzymes in the metabolic pathways of glutamate and GABA. Epilepsy Res. 1995;22:1‐11.Google Scholar
  56. 56.
    Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma‐aminobutyric acid in patients with epilepsy. Ann Neurol 1996;39:95‐99.Google Scholar
  57. 57.
    Mc Lean MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994;44(Suppl 5):S17‐S22.Google Scholar
  58. 58.
    Taillian KB, Nahata MC, Low W, Tsao C‐Y. Gabapentin Associated with Aggressive Behavior in Pediatric Patients with Seizures. Epilepsia 1996;37(5): 501‐502.Google Scholar
  59. 59.
    Gustavson LE, Mengel HB. Pharmacokinetics of Tiagabine, a g‐Aminobutyric acid‐Uptake Inhibitor, in Healthy Subjects After Single and Multiple Doses. Epilepsia 1995;36(6):605‐611.Google Scholar
  60. 60.
    So EL, Wolff D, Graves NM, Leppik IO, Cascino GD, Pixton GC et al. Pharmacokinetics of tiagabine as add‐on therapy in patients taking enzyme‐inducing antiepilepsy drugs. Epilepsy Res. 1995;22:221‐226.Google Scholar
  61. 61.
    Suzdak PD, Jansen JA. A Review of the Preclinical Pharmacology of Tiagabine: A Potent and Selective Anticonvulsant GABA Uptake Inhibitor. Epilepsia 1995;36(6):612‐626.Google Scholar
  62. 62.
    Gower AJ, Noyer M, Verloes R, Gobert J, Wülfert E. ucb L059, a novel anti‐convulsant drug: pharmacological profile in ani mals. Eur Pharmacol 1992;222:193‐203.Google Scholar
  63. 63.
    Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur Pharmacol 1993;232:147‐158.Google Scholar
  64. 64.
    Edelbroek PM, De Wilde‐Ockeloen JM, Kasteleijn‐Nolst Trenité DGA, Alpherts WCJ, Meijer JWA. Evaluation of the pharmacokinetic and neuro‐psychometric parameters in chronic co‐medicated epileptic patients of three increasing dosages of a novel anti‐epileptic drug, ucb L059 250 mg capsules per os each dose during one week followed by two weeks placebo. Epilepsia 1993:34(2):7.Google Scholar
  65. 65.
    Kasteleijn‐Nolst Trenité DGA, Marescaux C, Stodieck S, Oosting J, Edelbroek PM. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996 (in press).Google Scholar
  66. 66.
    Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB. Topiramate: Preclinical Evaluation of a Structurally Novel Anticonvulsant. Epilepsia 1994;35(2):450‐460.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • D.G.A. Kasteleijn‐Nolst TrenitÄ
    • 1
  • P.M. Edelbroek
    • 1
  1. 1.Instituut voor EpilepsiebestrijdingHeemstedeThe Netherlands

Personalised recommendations